Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Sanofi to take on lead Inhibrx candidate in $2.2bn deal
(Sharecast News) - Inhibrx announced an agreement with Sanofi on Tuesday, under which Sanofi subsidiary Aventis will acquire all assets and liabilities associated with INBRX-101, a recombinant alpha-1 antitrypsin (AAT) augmentation therapy currently being trialled for alpha-1 antitrypsin deficiency (AATD) treatment. At the same time, non-101 assets and liabilities including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline, and corporate infrastructure, would form a new publicly-traded entity called Inhibrx Biosciences.
Under the deal, Sanofi would merge with Inhibrx, with each Inhibrx shareholder receiving $30.00 per share in cash, one contingent value right per share for a potential $5.00 cash payment upon a regulatory milestone, and one SEC-registered, publicly-listed share of the
new Inhibrx for every four shares of Inhibrx currently held.
Sanofi would also retire Inhibrx's outstanding third-party debt and fund the new Inhibrx with $200m in cash, while retaining an 8% equity interest.
The boards of both Inhibrx and Sanofi unanimously approved the transaction.
They said the total transaction value, combining the upfront cash portion, contingent value payment, and debt assumption, was estimated at $2.2bn.
Inhibrx shareholders would own 92% of the new Inhibrx, which would be capitalised with $200m in cash.
Following the merger, the new Inhibrx would continue to operate under the 'Inhibrx' name, with Mark Lappe serving as chairman and chief executive officer, along with the current management team.
Sanofi was intending to finance the acquisition using available cash resources, with completion contingent on the new Inhibrx spin-off transaction and customary closing conditions, including regulatory approvals and approval by Inhibrx's shareholders.
The transaction was expected to close in the second quarter of 2024.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.